ETD001

ETD001 is a long-acting ENaC inhibitor, with an IC50 of 57.5 nM in cultured HBE cells. ETD001 can be used in the study for cystic fibrosis[1][2].

Product Specifications

CAS Number

[2227484-71-9]

UNSPSC

12352005

Target

Sodium Channel

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/etd001.html

Purity

98.85

Solubility

DMSO : 60 mg/mL (ultrasonic)

Smiles

OC(C(F)(F)F)=O.[O-]C(C(F)(F)F)=O.CC[N+](C1=C2)=C(CNC(C3=C(N)N=C(NC=C4)C4=N3)=O)N(CC)C1=CC=C2C(N5CCC(CC5)N(C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=O

Molecular Formula

C41H57F6N9O16

Molecular Weight

1045.93

References & Citations

[1]Henry Danahay, et al. Optimisation of a novel series of ENaC inhibitors, leading to the selection of the long-acting inhaled clinical candidate ETD001, a potential new treatment for cystic fibrosis. Eur J Med Chem. 2025 Jan 15:282:117040.|[2]Henry Danahay, et al. ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivo. J Cyst Fibros. 2024 Jun 7:S1569-1993 (24) 00081-X.